---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-001213"
form_type: "8-K"
ticker: "MEDP"
cik: "0001668397"
company_name: "Medpace Holdings, Inc."
filed_at: "2022-02-14T23:59:59+00:00"
generated_at: "2026-06-27T08:26:37.822176+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medpace Q4 revenue up 18.8% to $308.6M; full year revenue +23.4%; Board approves $300M buyback increase

## Summary
- Q4 2021 GAAP net income $50.0M ($1.32 EPS) vs $50.9M ($1.35 EPS) prior year; net income margin 16.2%.
- Full year 2021 GAAP net income $181.8M ($4.81 EPS) vs $145.4M ($3.84 EPS); net income margin 15.9%.
- Net new business awards Q4 $458.7M (book-to-bill 1.49x), up 27.9% YoY; backlog $1,997.1M (+29.5%).
- EBITDA Q4 $61.4M (19.9% margin) vs $60.2M (23.2%) prior year; full year EBITDA $223.1M (19.5% margin).
- Board increased stock repurchase program by $300 million; program has no set expiration.

## SEC filing metadata
- accession: 0000950170-22-001213
- form_type: 8-K
- ticker: MEDP
- cik: 0001668397
- company_name: Medpace Holdings, Inc.
- filed_at: 2022-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668397/000095017022001213/0000950170-22-001213-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668397/000095017022001213/medp-20220210.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-001213
- JSON: https://secwatch.observer/filing/0000950170-22-001213.json
- Plain text: https://secwatch.observer/filing/0000950170-22-001213.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.